{"schema_version":"1.0","type":"article","title":"After 20 Years, Have HDAC Inhibitors Finally Found Their Role? Why ABT-301 Could Become a Next-Generation Combination Backbone","url":"https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone-en.md","lang":"en","date":"2026-08-11","publish_at":"2026-08-11T08:00:00+08:00","updated_at":"2026-08-11","category":"商業分析系列","topic":"商業分析系列","tags":["AnBogen Therapeutics","ABT-301","imofinostat","HDAC inhibitor","Chidamide","pMMR colorectal cancer","cancer immunotherapy","Taiwan biotech"],"summary":"Chidamide has brought HDAC inhibition back into solid-tumor development. ABT-301 must now show that a wider therapeutic window, triplet combinability, and human immune-mechanism data can support a next-generation combination backbone.","key_points":[],"facts":[],"sections":["1. The HDACi Problem Was Never Lack of Activity — It Was Lack of Durability and Combinability","2. Chidamide Has Reopened the Class — and Raised the Bar","3. ABT-301’s Differentiation: The Thesis Is the Therapeutic Window, Not ‘16× Potency’","4. Phase I: 23 Patients Put the Mechanism Into Humans — Enough to Advance, Not Enough to Call the Outcome","5. The Triplet Is the Inflection Point: Four Gates Matter More Than One ORR Number","6. ABT-301’s Market Expansion Path: Set the Valuation Floor, Add Cross-Tumor Optionality, Earn the Platform Premium","Conclusion: Chidamide Has De-Risked the Class. ABT-301 Still Has to De-Risk the Asset","References"],"references":[{"title":"[HUYABIO International Delivers Significant Landmark Phase 3 Results in Advanced Melanoma]","source":"","date":"","url":"https://huyabio.com/huyabio-international-delivers-significant-landmark-phase-3-results-in-advanced-melanoma/"},{"title":"[Combined anti-PD-1, histone deacetylase inhibitor and anti-VEGF treatment in MSS/pMMR colorectal cancer (Nature Medicine, CAPability-01)]","source":"","date":"","url":"https://www.nature.com/articles/s41591-024-02813-1"},{"title":"[Phase I first-in-human trial of ABT-301, an oral pan-HDAC inhibitor in patients with advanced solid tumors (JCO 2023 abstract e15137)]","source":"","date":"","url":"https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e15137"},{"title":"[Imofinostat - NCI Drug Dictionary]","source":"","date":"","url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/imofinostat"},{"title":"[Anbogen Therapeutics - ABT-301 clinical and AACR updates]","source":"","date":"","url":"https://anbogen.com/en/news/cCCcD7dA6dcf"},{"title":"[ClinicalTrials.gov: ABT-301 + Tislelizumab + Bevacizumab in pMMR/non-MSI-H colorectal cancer]","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT07244705"},{"title":"[Chipscreen Biosciences - Chidamide/Tucidinostat development history]","source":"","date":"","url":"https://www.chipscreen.com/en/news/company-news/1178.html"},{"title":"[Phase II randomized trial of first-line pembrolizumab and vorinostat in metastatic NSCLC: final results]","source":"","date":"","url":"https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.9125"},{"title":"[Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial]","source":"","date":"","url":"https://www.nature.com/articles/s43018-025-01004-2"},{"title":"[Anbogen Therapeutics Pre-TPEx Investor Presentation (2026)]","source":"","date":"","url":"https://mopsov.twse.com.tw/nas/STR/778420260429E001.pdf"},{"title":"[Credence Research: Global Checkpoint Inhibitor Refractory Cancer Drugs Market]","source":"","date":"","url":"https://www.credenceresearch.com/report/checkpoint-inhibitor-refractory-cancer-market"},{"title":"[Pancreatic Cancer Market Size and Forecase 2026-2035 (Research Nester)]","source":"","date":"","url":"https://www.researchnester.com/reports/pancreatic-cancer-market/5299"},{"title":"[Brain Cancer Market Trends for 2026 (Towards Healthcare)]","source":"","date":"","url":"https://www.towardshealthcare.com/insights/brain-cancer-market-sizing"},{"title":"[Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer]","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit/"}],"images":[{"alt":"Figure 1 | Three barriers have constrained HDAC inhibitors in solid tumors for two decades: safety and combinability, a narrow therapeutic window, and the failure of early responses to consistently translate into PFS and OS.","url":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/figure-01.png"},{"alt":"Figure 2 | Chidamide has delivered two solid-tumor proof points: CAPability-01 achieved a 44% ORR in MSS metastatic colorectal cancer, while HBI-8000 plus nivolumab met the primary PFS endpoint in global Phase III melanoma. Hematologic toxicity and combination burden remain key points of comparison.","url":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/figure-02.png"},{"alt":"Figure 3 | ABT-301’s differentiation thesis links HDAC3 targeting, immune-microenvironment remodeling, and resistance biology to human exposure and, ultimately, combination-treatment validation.","url":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/figure-03.png"},{"alt":"Figure 4 | Phase I established the human foundation for ABT-301 — safety, preliminary activity, target engagement, and a workable dose range — but not yet comparative proof.","url":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/figure-04.png"},{"alt":"Figure 5 | The pMMR colorectal cancer triplet creates four sequential value inflection points: combinability, reproducible efficacy, durability, and human mechanistic validation — the evidence needed to determine whether ABT-301 can become a true combination backbone.","url":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/figure-05.png"},{"alt":"Figure 6 | ABT-301’s value-unlocking path: MSS colorectal cancer sets the valuation floor; pancreatic and brain tumors add cross-tumor optionality; and repeatable success with multiple partner therapies is what ultimately supports a platform premium. Market figures are shown for demand context only.","url":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/figure-06.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-11）。After 20 Years, Have HDAC Inhibitors Finally Found Their Role? Why ABT-301 Could Become a Next-Generation Combination Backbone。https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-11-anbogen-abt301-next-generation-hdaci-backbone.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}